Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Groningen – page 21

557 clinical trials in Groningen, The Netherlands across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Groningen at a glance
557
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

557 trials in Groningen

Open in trial search

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate
  • Sponsor:Rheacell GmbH & Co. KG

Sjogren's syndrome

Not yet recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Phenylketonuria

Not yet recruiting

A Phase 2 Study of MZE782 Safety, Tolerability, and Efficacy in Adults with Phenylketonuria

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Maze Therapeutics Inc.

Glioblastoma

Not yet recruiting

Study of [18F]MC225 PET to Assess Blood‑Brain Barrier Function in Patients with Suspected Glioblastoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Mc225
  • Sponsor:Universitair Medisch Centrum Groningen

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Obesity

Not yet recruiting

A study of NNC0638-0355 to evaluate safety, tolerability and weight loss with multiple doses in adults with obesity or overweight

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer stage III

Not yet recruiting

Fluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitair Medisch Centrum Groningen

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Groningen

What the registry says about research in the country

01 Cardiovascular Research

Advanced studies focusing on heart disease and cardiovascular conditions, including innovative treatments for ATTR amyloidosis and prevention strategies for heart failure.

  • Cardiomyopathy Treatments
  • Heart Failure Prevention
  • Peripheral Arterial Disease

Multiple trials exploring novel therapeutic approaches and preventive measures for various cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including melanoma and lung cancer, with particular focus on innovative treatment approaches and metastatic disease management.

  • Advanced Breast Cancer
  • Small Cell Lung Cancer
  • Brain Metastases

Investigation of targeted therapies and combination treatments for improved patient outcomes.

03 Metabolic Disorders

Clinical investigations focusing on obesity and type 2 diabetes, testing new therapeutic approaches for weight management and metabolic control.

  • Weight Management
  • Diabetes Treatment
  • Metabolic Health

Evaluation of novel medications combined with lifestyle interventions for optimal patient care.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.